

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Beijing Airdoc Technology Co., Ltd.**  
**北京鷹瞳科技發展股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2251)**

**VOLUNTARY ANNOUNCEMENT**  
**PURCHASE OF SHARES PURSUANT TO**  
**THE 2022 EQUITY INCENTIVE SCHEME**

This announcement is made by Beijing Airdoc Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis. Reference is made to the announcement of the Company dated January 13, 2023 and the circular dated March 10, 2023 in relation to the adoption of the 2022 Equity Incentive Scheme. Capitalized terms used herein shall have the same meanings as those defined in the aforesaid announcement and circular unless the context requires otherwise.

Pursuant to the scheme rules of the 2022 Equity Incentive Scheme, the Incentive Shares grantable under the 2022 Equity Incentive Scheme shall be satisfied by the H Shares to be purchased on market by the Trustee as instructed by the Company. The purchase price shall not exceed the average closing price of the Shares as stated in the Stock Exchange’s daily quotation sheets for the fifteen business days immediately preceding the date of purchase. Such purchase shall be funded by the Company.

In order to satisfy the 3,107,040 Incentive Shares granted (the “**Grant**”) to Mr. Zhang Dalei, an executive Director and the chairman of the Board, the Company instructed the Trustee to purchase such Incentive Shares in the open market. The Grant was resolved by the Board on January 13, 2023, the date on which the Board also resolved to approve and propose to the Shareholders the adoption of the 2022 Equity Incentive Scheme. The 2022 Equity Incentive Scheme was subsequently approved by the Shareholders at the extraordinary general meeting of the Company held on March 30, 2023.

Since September 18, 2023 and up to the date of this announcement, the Trustee purchased a total number of 787,700 H Shares in the open market, at daily average trading prices ranging from HKD10.17 to HKD11.94. The share purchase was funded by the idle funds obtained from the sales activities during the Group's ordinary course of business.

The Company may instruct the Trustee to make further purchases pursuant to the Grant and any future grants under the 2022 Equity Incentive Scheme, and may further announce details of such grant and share purchase, including the number of H Shares to be granted and purchased, and the price thereof, from time to time.

By order of the Board  
**Beijing Airdoc Technology Co., Ltd.**  
**Mr. ZHANG Dalei**  
*Chairman of the Board*

Hong Kong, December 15, 2023

*As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Dr. CHEN Yuzhong, Mr. CHEN Hailong and Ms. WANG Lin as executive Directors; Mr. CHEN Xin as a non-executive Director; and Mr. NG Kong Ping Albert, Dr. WU Yangfeng and Dr. HUANG Yanlin as independent non-executive Directors.*